- Home
- FINS vs SGHT Comparison
FINS vs SGHT Comparison
Compare FINS & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FINS
- SGHT
- Stock Information
- Founded
- FINS 2019
- SGHT 2011
- Country
- FINS United States
- SGHT United States
- Employees
- FINS N/A
- SGHT N/A
- Industry
- FINS Finance/Investors Services
- SGHT Medical Specialities
- Sector
- FINS Finance
- SGHT Health Care
- Exchange
- FINS Nasdaq
- SGHT Nasdaq
- Market Cap
- FINS 321.1M
- SGHT 304.4M
- IPO Year
- FINS N/A
- SGHT 2021
- Fundamental
- Price
- FINS $12.88
- SGHT $6.35
- Analyst Decision
- FINS
- SGHT Hold
- Analyst Count
- FINS 0
- SGHT 8
- Target Price
- FINS N/A
- SGHT $6.75
- AVG Volume (30 Days)
- FINS 78.0K
- SGHT 157.2K
- Earning Date
- FINS 01-01-0001
- SGHT 08-01-2024
- Dividend Yield
- FINS 9.97%
- SGHT N/A
- EPS Growth
- FINS N/A
- SGHT N/A
- EPS
- FINS N/A
- SGHT N/A
- Revenue
- FINS N/A
- SGHT $79,395,000.00
- Revenue This Year
- FINS N/A
- SGHT $3.63
- Revenue Next Year
- FINS N/A
- SGHT $11.40
- P/E Ratio
- FINS N/A
- SGHT N/A
- Revenue Growth
- FINS N/A
- SGHT N/A
- 52 Week Low
- FINS $11.61
- SGHT $1.04
- 52 Week High
- FINS $12.57
- SGHT $8.45
- Technical
- Relative Strength Index (RSI)
- FINS 63.33
- SGHT 46.39
- Support Level
- FINS $12.75
- SGHT $6.12
- Resistance Level
- FINS $12.97
- SGHT $7.02
- Average True Range (ATR)
- FINS 0.14
- SGHT 0.40
- MACD
- FINS 0.00
- SGHT 0.01
- Stochastic Oscillator
- FINS 80.85
- SGHT 32.04
About FINS Angel Oak Financial Strategies Income Term Trust of Beneficial Interest
Angel Oak Financial Strats Income Term is a non-diversified, closed-end management investment company. The fund's objective is to seek current income with a secondary objective of total return. In pursuing its investment objective, the fund invests mainly in debt issued by financial institutions, including subordinated debt, unrated debt, senior debt, and high-yield securities.
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.